

tems should be expected to provide a drug output with about 50% of the particles below 5.0 µm mass median diameter. It is important to obtain an acceptable range of aerosol particle sizes because of the way in which these are deposited in the tracheobronchial tree.¹⁻⁵

Practical definitions

Jet nebuliser: a nebulising chamber where an aerosol is generated from a flow of gas from an electrical compressor or from a compressed gas supply (air or oxygen). The gas passes through a very small hole (the jet or Venturi) resulting in liquid being sucked up through the small hole from the chamber base and atomised. The resultant large particles then impact upon baffles to generate small respirable particles.⁶

Ultrasonic nebuliser: an electrically driven system whereby a rapidly vibrating piezoelectric crystal vibrates the drug solution and produces aerosol particles of a respirable size.⁶

Flow rate through the nebuliser: the flow rate of gas, whether from a compressed source or from a compressor, that actually drives the nebuliser chamber. It is not the same as the flow rate from the compressor which will often be considerably higher.⁷ It is obtained by producing a pressure-flow rate curve for the nebuliser. Recordings of circuit pressure are made from zero flow (maximum pressure) to maximum flow (minimum pressure) using a rotameter, a compressor unit (or flow generator), and pressure measuring device. By substituting the nebuliser chamber for the rotameter the pressure in the circuit can be obtained with a constant flow rate from the flow generator. From the pressure-flow curve the flow rate at the nebuliser can be obtained.⁷

Volume output from the nebuliser: the volume of solution leaving the nebuliser chamber. Whilst useful as a general guide to nebuliser performance, it does not give precise information about the actual drug output.²

Drug output from the nebuliser: the actual amount of drug that is released during nebulisation. Because of a variety of factors, including evaporation, a precise measure of drug output (as opposed to volume output) must be assessed using marker techniques.⁸

Residual volume: the volume of solution left in a nebuliser chamber once nebulisation has ceased and all of the aerosol particles have been generated and have left the nebuliser chamber. It is an important volume to take into account

suggested that it should be at least 10% residual volume. It is important to take account of the desirable fill volume when comparing nebuliser drugs in prepackaged ampoules.
The definitions of aerosol output, drug particles, mass median diameter (MMD), median aerodynamic diameter (MAD), and respirable output, and respirable volume are given in the paper by O'Callaghan and colleagues on page S35.

Factors affecting nebuliser performance

The general term "nebuliser" usually refers to the combination of the nebuliser chamber and the compressor. Jet nebulisers usually give a constant output, but to prevent breathlessness breath-enhanced nebulisers are available where the output is enhanced in the inhaled phase. Ultrasonic nebulisers are effective for children, robust and more expensive than jet systems and are generally not used for domiciliary therapy.

The major use of nebulisers is to deliver bronchodilator therapy. The atomisation of the nebuliser chamber for administering bronchodilators is different from that required to deliver other drugs such as antibiotics or pentamidine.

The output of a nebuliser is determined by a combination of factors which must be taken into account, and will depend on (1) the size of the nebuliser chamber,⁶ (2) the flow rate of driving gas and the performance of the compressor,^{7,10,11} (3) the volume of drug (fill volume) of the drug at the time of nebulisation,^{9,12} (4) the time taken to nebulise a solution of drug,^{7,9} (5) the viscosity of the solution, and concentration of the drug, (6) the residual volume,⁹ and (7) the volume of nebuliser chamber during nebulisation.

The volume output and particle size of saline, salbutamol, terbutaline, and ipratropium bromide are similar.¹⁴ In aqueous solutions the volume output of saline is slower (fig 1).^{13,15} The output of saline may be similar to salbutamol although it is a suspension. However, the volume output from a nebuliser is not directly proportional to drug output,⁸ and the drug output and availability are different between bronchodilators, antibiotics, and steroids. The volume output is simple and proportional to the performance of nebuliser systems.^{7,16}

Respiratory
Department,
Bristol Royal
Infirmary,
Bristol BS2 8HW, UK
A H Kendrick

Department of
Medicine,
c/o Respiratory
Department,
Bristol Royal
Infirmary,
Bristol BS2 8HW, UK
E C Smith

Department of
Respiratory Medicine,
Royal Shrewsbury
Hospitals NHS Trust,
Shrewsbury SY3 8XQ,
UK
R S E Wilson

Correspondence to:
Dr A H Kendrick.

solutions with a specific gravity of 1 have similar rates of output. The slightly more viscous antibiotic solution has a slightly slower rate of output. Data from reference 14.

rainies. Any clinical data that can be obtained on the clinical use of the device should also be obtained.

Selecting nebulisers and compressors

The choice of nebuliser and compressor depends on various factors including cost, ease of use and of maintenance, and overall performance. There are many nebuliser chambers and compressors available. Choice should be based on assessment of the systems and comments from other users. It is not advisable simply to pick a nebuliser chamber and a compressor at random. As will be discussed below, the matching of a nebuliser and compressor is important to achieve optimal performance. Furthermore, under certain circumstances par-

Nebuliser/compressor combination

The performance of a given nebuliser is closely linked to the flow of the compressor and, hence, the performance of the compressor chosen to drive the nebuliser chamber is therefore important to use a nebuliser chamber and compressor that delivers an acceptable volume of output with an acceptable range of respiratory rates over an acceptable period of time for the patient.^{7 12 16-23}

Table 1 Examples of combinations of compressors and nebuliser chambers supplied for bronchodilator therapy. The compressors have been divided into high, medium, and low flow rates and have been used with the nebuliser chambers indicated

Flow rate	Compressor	Nebuliser chambers sold with compressor unit	Multivoltage
High flow rate (>6.0 l/min)	AFP Classic	MicroMist	No
	AFP Aquillon	MicroMist	No
	AFP Ultima	MicroMist	Recharge
	AFP Tourer	MicroMist	Yes
	Flaem Nuova Combineb	Flaem Nuova Type 3	Yes
	Flaem Nuova Micelfluss Pro	Flaem Nuova Type 2	Yes
	Medic-Aid CR50	Medic-Aid Sidestream	No
	Medic-Aid CR60*	Medic-Aid Ventstream	No
	Medic-Air Freeway		Yes
	Gast*†		?
	Inspiron*	MiniNeb, Incenti-Neb	No
	Medix M Flo	Medix A11	No
	Medix AC2000*	Medix A11	No
	Medix World Traveller	Medix A11	Yes
	Medix Econoneb	Medix A11	No
	Medix Minor*†	Cirrus	No
	Medix Turboneb	Cirrus	No
	Porta-Neb	Medic-Aid Sidestream	No
		Medic-Aid Ventstream	
		Porta-Neb Multi	
	SunMist Plus	Perma Neb	Yes
			No
Medium flow rate (4.0-6.0 l/min)	Aeroneb HP†	Cirrus	No
	Atomolette†	Own	No
	Flaem Nuova M70	Flaem Nuova Type 2	No
	NebuPump†	Acorn	No
	Novair II	Cirrus	No
	Pari InhalierBoy†	Own	No
	Pari TurboBoy	Pari LC Plus, LC Plus Junior	No
	Pari JuniorBoy	Pari LC Plus, LC Plus Junior	No
	Pulmo-Aide†	Own	No
	SunMist	Perma Neb	No
	DeVilbiss Traveller	Perma Neb	Yes
	Low flow rate (<4.0 l/min)	Aeroneb Standard†	Own, Cirrus
Pari WalkBoy		Pari LC Plus,	Yes
Aeroneb HP†		Own	No
Others	Aerolyser CF1B†	Wright	Yes
	Aerolyser CF1R†	Respi-Neb	Yes
	Aerolyser 216†	Respi-Neb	Yes
	Flaem Nuova Travelneb	Flaem Nuova Type 3	Yes
	Henley HCU-1†	Hudson MK II	Yes

* Wilson and Steventon have tested these compressors with 19 nebuliser chambers: Acorn, Aerflo, Cirrus, Hudson II, Jet set, MicroCirrus, MicroNeb III, MiniNeb, Sandoz, Suremist, Turret Turbo, Unicorn, Unimist and Wee Neb. With these compressors they all achieved flow rates at the nebuliser of >6.0 l/min.

† These devices may not be currently available but are included since they may still be in use.

Flaem Nuovo Type 3	0.5	8.0	?	?	?	57	82
Hudson Neb MKII	?	?	?	?	?	50	?
Hudson UD I	2.3	17	?	?	?	?	82
Hudson UD II	1.4	10	25	33	?	?	79
Incenti-Neb	?	20	?	?	?	?	54
Jet set	?	?	?	?	?	?	?
MicroCirruss†	1.2	10	?	?	?	?	90
MicroMist	?	10	?	?	?	?	76
MicroNeb	0.9	13	28	59	?	?	78
MiniNeb	2.3	38	41	51	?	?	79
Pari Boy	2.0	9	50	64	?	?	64
Pari LC Plus	1.0	8	50	50	?	?	60
Pari LC Plus Junior	0.9	8	55	55	?	?	54
Perma Neb	1.2	9	39	75	?	?	70
Raindrop	?	?	?	?	?	?	?
Respi-Neb	?	?	?	?	?	?	?
Respirgard II†	1.3	9	?	?	?	?	?
Sandoz	?	?	?	?	?	?	?
Medic-Aid Sidestream	0.7	12	?	?	?	?	83
System 22 Mizer	2.0	15	?	?	?	?	73
Turret Turbo	?	20	?	?	?	?	73
Unicorn 1035	?	10	?	?	?	?	68
Unineb	?	?	?	?	?	?	?
Upmist	?	?	?	?	?	?	?
Venticaire	?	?	?	?	?	?	?
Medic-Aid Ventstream	1.0	10	?	?	?	?	86
Wee Neb	?	?	?	?	?	?	?
Wright	?	20	?	?	?	?	83

The data in this table have been compiled from various sources and provide a guide only. Whilst the residual volumes are accurate, the percentage of solution nebulised at 5 and 10 minutes is the best figure obtainable for a fill volume of 2–2.5 ml and is generally taken from data obtained with its retail compressor. The percentage of particles under 5 µm is taken from various sources. Where a ? appears there are no data currently available from any known source.
* Depends on configuration of nebuliser chamber (Type 2) and on type of compressor unit. Data are for diaphragm compressors.
† Data with pentamidine.

BRONCHODILATOR THERAPY

We have divided some currently available nebuliser/compressor combinations into three bands based on the flow rate at the nebuliser (table 1). High flow rate combinations produce more than 50% of the particle size output less than 5 µm diameter and have an MMD of less than 5 µm.^{7 16 19–21} The lower flow rate combinations have less than 40% of their particle size output below 5 µm diameter and an MMD of more than 9 µm. The performance of some of the nebuliser chambers is given in table 2. Particle size distributions may differ with different combinations of nebuliser and compressor (fig 2). Breath assisted nebulisers such as the Ventstream and Pari LC have been shown to have improved performance.²³

An important point about nebulising bronchodilator drugs is whether or not there is a need for a specific combination or combinations. Whilst there are criteria for attaining an optimal performance, this may not matter in practice since subjective benefit and objective bronchodilatation are the most important factors. There are a number of nebuliser/compressor combinations currently available that do not achieve the standard criteria.⁷ However, these systems are still being used and there have been no reports to suggest that long term use of a

poor performance system has resulted in a reduction in the quality of life or an increase in hospital admissions. Part of the reason for this is probably that the doses of bronchodilator drugs being administered are large enough that even inefficient systems deliver enough drug to ensure maximal bronchodilatation.




Figure 2 Two examples of particle distribution. The solid line shows the cumulative percentage of particles with particle sizes for a high flow rate combination (AeroNeb Standard; flow rate 7 l/min) and the dashed line shows the cumulative percentage of particles with particle sizes for a low flow rate combination (AeroNeb Standard; flow rate 3 l/min). The fill volume was 2.5 ml of sterile water. For the Aquillon combination the percentage of particles less than 5 µm was 83%, while for the AeroNeb Standard it was 35%. Based on reference 7.

to be used with antibiotics.^{16,24-28} A powerful, continuously rated compressor should be used (table 3). Various nebuliser chambers have been shown to be acceptable, although in some cases nebulisation times were longer than is perhaps ideally required by the patient.²⁹

but in approximately half the time. Data from Sidestream nebuliser under simulated tidal compressed air to drive the nebuliser. The fill volume is 0.5 ml. For a fill volume of 2.5 ml nebulisation "dryness" was six minutes which increased using the 4 ml fill volume. The 70% increase in nebulisation time increased the drug output. Data from reference 12. Reproduced from permission.

MUCOLYTICS AND SALINE

Where mucolytics such as acetylcysteine are used, standard delivery systems, as shown in table 1, can be used. The high and medium flow rate systems appear to be adequate,^{30,31} especially since there appears to be little difference in the rate of output of saline and of bronchodilators.¹⁴

RHDNASE

Current recommendations are based on limited data.³²⁻³⁵ rhDNase should be nebulised using a jet nebuliser since ultrasonic nebulisers may inactivate it or have unacceptable aerosol characteristics. Recommended combinations are given in table 4.

STEROIDS

These can be nebulised with medium or high power systems as shown in table 5.

Volume-time output and fill volume

Four criteria should be considered:

(1) The minimum initial fill volume is determined by the size of the residual volume of the nebuliser chamber. The larger the residual volume, the greater the initial fill volume will need to be.^{9,17,22} The residual volume of the modern, small volume, nebuliser chambers is less than 1.0 ml (table 2) and for these a fill volume of 2.0–2.5 ml of drug solution is

enough. Increasing the fill volume of a small volume nebuliser (Sidestream) will deliver the same amount of drug but over a longer period of time (fig 3).¹² Where the residual volume is greater than 1.0 ml, a larger initial fill volume is required. Since many nebuliser chambers are available in prepackaged ampoules of 2.5 ml, it is important to ensure that the nebuliser chamber used by a patient is not a small residual volume or that the nebuliser is instructed to dilute the contents of the ampoule with normal saline and to make up the residual fill volume to at least twice the residual volume. Table 6 lists suitable combinations of nebuliser chambers and ampoules.

(2) The time taken to deliver a given volume is important for patient compliance. The minimum time for nebulisation is 5 minutes. Patients will generally not accept nebulisation times (fig 4), especially if the treatment is required several times per day.²⁹

(3) The end point of nebulisation should be defined. There is some confusion over nebulising "to dryness" is confusing and is difficult for them to define. Patients should nebulise continuously until the residual volume approaches the residual volume. "spluttering" occurs.³⁶ At this point

Table 4 Recommended nebuliser/compressor combinations for rhDNase therapy

Compressor	Nebuliser chamber
Pulmo-Aide	Hudson T Up-draft II Airlife Misty A11
Pari InhalierBoy	Pari LL, Pari LC
Pari TurboBoy	Pari LC Plus
Aiolos	Aiolos
Medic-Aid Porta-Neb	Medic-Aid Sidestream
Medic-Aid CR50	Medic-Aid Sidestream
Medic-Aid CR60	Medic-Aid Sidestream
AFP Aquillon	MicroMist

Data from studies using Pulmozyme.

Table 5 Examples of nebuliser/compressor combinations suitable for corticosteroid therapy

Compressor	Nebuliser chamber
Medic-Aid Porta-Neb	Medic-Aid Vents Medic-Aid Sidestream Cirrus Hudson Turret
Medic-Aid Freeway Medic-Aid CR60/CR50	Medic-Aid Vents Cirrus, A11 DeVilbiss 646 Hudson Up-draft Turret
AFP Aquillon	MicroMist
AFP Tourer	Medic-Aid Sidestream
AFP Ultima	Medic-Aid Sidestream
Pari TurboBoy	Pari LC Plus, LC
Pari JuniorBoy	Pari LC Plus, LC

Data from various sources. This list is not exhaustive. Other devices may be suitable.

Sodium cromoglycate	Intal	2.0	As above for 2.0 ml
Dornase alpha	Pulmozyme	2.5	Hudson UD II, Acorn, M Sidestream, Medic-Aid Ventstream, Aiolos, Pari

It is taken that at least 50% of the drug solution should be available for nebulisation and without the need for normal saline. Data from British National Formulary.

† Also available in 1.0 ml ampoules containing 250 µg/ml. The 2.0 ml ampoule contains 500 µg/ml. Use of the 2.0 ml ampoule will need dilution as no nebuliser chamber has a residual volume of less than 0.5 ml.




Figure 4 Patient acceptability of different durations of nebuliser treatments. Most patients preferred a treatment time of 10 minutes or less. Unpublished data from R S E Wilson.




Figure 5 Recognition by patients of "dryness" at the end of nebulisation. The combination of a Charles Austen compressor with a MiniNeb nebuliser would usually reach residual volume in 10 minutes with a fill volume of 2.0-2.5 ml. Following explanation of the meaning of "dryness", patients timed the system to "dryness" with a stopwatch in minutes and seconds (n = 39 episodes). Unpublished data from J Pugh and R S E Wilson.

volume output is reduced because of the reduction in nebulisation, drug output remains high for a period of time (fig 6). This means that patients should be told to nebulise until the nebuliser is empty. Nebulising occurs and then to continue for a minute. Previous tests should have shown that with the fill volume used, the system should reach this point in 10 minutes or less. It is important to ensure that the compressor/nebuliser combination is working efficiently and has no faults.

(4) During nebulisation (particularly with small units) large particles tend to adhere to the side of the nebuliser. Adherence becomes a problem as the nebuliser ages. These large particles are encouraged to fall back into the well of the nebuliser by tapping the side of the nebuliser. It is noted once the nebuliser begins to "splutter" that there is evidence that this may improve output by up to 50% over a given period of time (unpublished data).

Ease of use

The choice of nebuliser chamber should, to some extent, be based on its ease of use. In general, chambers should (1) not have any components that can be easily swallowed by children (ideally, all nebulisers should have a removable top and the single-chamber design); (2) be easily disassembled and assembled by patients of all ages (this is particularly important in the elderly and those whose manual dexterity is significantly impaired); and (3) employ a chamber design that is left connected to the compressor, rather than being a surface, or be mounted on the compressor itself, and so be filled easily.

Mouthpieces/face masks and circuits

Lung deposition is the same in both adults and children, when either a mouthpiece or a face mask can be used.^{37,38} Face masks are used for infants and younger children, and are preferred in some agencies. Mouthpieces are recommended for older children. If steroids or anticholinergics are being used, the mouthpiece should be changed after each use.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.